Management of Thyroglobulin Elevations

Introduction to Biochemical Incomplete Response

Biochemical incomplete response is defined as a negative neck ultrasound with thyroglobulin (Tg) levels > 1 ng/mL, requiring further investigation, according to the Annals of Oncology guidelines 1
The American Society of Clinical Oncology and European Society for Medical Oncology recommend Tg as the primary biochemical tumor marker and TgAb trends as additional prognostic information for DTC surveillance, with Tg serving as the cornerstone for biochemical surveillance of DTC recurrence 2, 1

Maintain TSH at 0.1-0.5 μIU/mL for biochemical incomplete response, as this level of suppression balances recurrence risk reduction with adverse effects of hyperthyroidism, based on recommendations from the Annals of Oncology 1
TSH suppression should be adjusted based on risk category, considering decreasing levothyroxine dose to allow serum TSH to increase toward the reference range if the patient is not at high risk for recurrence, as recommended by clinical guidelines from the American College of Oncology 3

Monitor Tg and perform neck ultrasound every 6-12 months, and calculate Tg doubling time (short doubling time <1 year indicates worse prognosis), as suggested by the Annals of Oncology guidelines 1
The American College of Radiology suggests monitoring Tg and TgAb levels every 6-12 months, as rising TgAb levels may indicate recurrent/persistent disease even when Tg remains low, and declining TgAb levels generally suggest successful treatment 4
The American Thyroid Association and American College of Oncology recommend a follow-up protocol that depends on risk stratification, with Tg measurement every 12-24 months for low-risk patients, every 6-12 months for intermediate-risk patients, and every 3-6 months for high-risk patients, with a moderate strength of evidence supporting this approach 2, 1

Consider FDG-PET/CT, especially if Tg is rising or Tg doubling time is short (<1 year), according to the Annals of Oncology guidelines 1
Consider whole-body scintigraphy to identify RAI-avid disease if FDG-PET is negative, as recommended by the Annals of Oncology 1

The following table summarizes the recommended imaging modalities:

Modality	Recommendation
Neck Ultrasound	first-line imaging modality for evaluating the thyroid bed and cervical lymph nodes
CT Neck/Chest with contrast	for evaluating neck and mediastinal lymph nodes
MRI	for evaluating liver, bones, and brain involvement
Whole Body Scintigraphy	to identify RAI-avid disease
FDG-PET/CT	for detecting RAI-refractory disease

Response to treatment can be categorized as:

Response Category	Criteria
Excellent	negative imaging, undetectable TgAb, and Tg <0.2 ng/ml or stimulated Tg <1 ng/ml
Biochemical Incomplete	negative imaging but Tg >1 ng/ml or stimulated Tg >10 ng/ml or rising TgAb levels
Structural Incomplete	imaging evidence of disease
Indeterminate	nonspecific imaging findings or Tg 0.2-1 ng/ml or stimulated Tg 1-10 ng/ml

Excellent response to treatment is managed with shift from suppressive to replacement LT4 therapy, annual physical examination, yearly Tg measurement on LT4, and yearly neck ultrasound, as recommended by the American Thyroid Association 2
Biochemical incomplete response is managed with maintenance of TSH at 0.1-0.5 μIU/ml, Tg and TgAb monitoring every 6-12 months, and neck ultrasound every 6-12 months, as recommended by the European Society for Medical Oncology 1
Structural incomplete response is managed with maintenance of TSH at 0.1 μIU/ml or lower, Tg and TgAb monitoring every 3-6 months, and imaging every 3-6 months, as recommended by the National Comprehensive Cancer Network 1

Neck ultrasound has limitations, including operator dependency, inability to visualize deep structures, and those shadowed by bone or air, and should not be relied upon solely, according to the Annals of Oncology guidelines 1
TgAb can interfere with Tg measurement when using immunometric assays, typically causing underestimation of Tg values, as reported by the Clinical and Laboratory Standards Institute 2
Ultrasensitive Tg assays have higher sensitivity but lower specificity, as stated by the American Society for Clinical Pathology 2
Liquid chromatography/tandem mass spectrometry (LC-MS/MS) may overcome TgAb interference, as recommended by the European Thyroid Association 1

Risk stratification according to staging systems (AJCC, ATA, ETA) is essential for patients with suspected or confirmed DTC, with the ATA recommending risk stratification based on thyroid cancer type, tumor size, and presence of lymph node metastases 6
Elevated thyroglobulin levels should be interpreted in the context of a patient's risk category, with low-risk patients having a 1-2% recurrence rate, intermediate-risk patients having a 2-4% recurrence rate, and high-risk patients having a 14% recurrence rate, as reported by the American College of Oncology, with a moderate strength of evidence supporting this association 1
The 5-year and 10-year mortality rates after diagnosis of distant metastases are 65% and 75%, respectively, according to the American College of Radiology, with a high strength of evidence supporting this association 1